Guided Therapeutics (GTHP) Net Income towards Common Stockholders (2010 - 2026)
Guided Therapeutics (GTHP) posted Net Income towards Common Stockholders of -$1.2 million for Q4 2025, down 52.36% sequentially from -$785000.0 in Q3 2025, and down 70.86% YoY from -$4.1 million in Q4 2024.
Guided Therapeutics (GTHP) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Guided Therapeutics has reported Net Income towards Common Stockholders for 16 years, with the latest figure at -$1.2 million in Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 70.86% year-over-year to -$1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.3 million (down 27.36% YoY) and the FY2025 annual result came in at -$3.3 million, down 27.36% from the prior year.
- Net Income towards Common Stockholders declined to -$1.2 million in Q4 2025 per GTHP's latest filing, from -$785000.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$51000.0 in Q3 2021 and troughed at -$1.9 million in Q4 2022.
- A 5-year average of -$845700.0 and a median of -$771500.0 in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2021 and 2022: Net Income towards Common Stockholders soared 82.87% in 2021, then tumbled 1966.67% in 2022.
- Over 5 years, Net Income towards Common Stockholders stood at -$509000.0 in 2021, then slumped by 264.83% to -$1.9 million in 2022, then surged by 74.74% to -$469000.0 in 2023, then slumped by 49.25% to -$700000.0 in 2024, then plunged by 70.86% to -$1.2 million in 2025.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$1.2 million, -$785000.0, and -$856000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Guided Therapeutics | 21.24 Mn | 21.23 Mn | - | -604,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -604,000.00 |
| Dec 31, 2025 | -1.20 Mn |
| Sep 30, 2025 | -785,000.00 |
| Jun 30, 2025 | -856,000.00 |
| Mar 31, 2025 | -463,000.00 |
| Dec 31, 2024 | -700,000.00 |
| Sep 30, 2024 | -692,000.00 |
| Jun 30, 2024 | -758,000.00 |
| Mar 31, 2024 | -441,000.00 |
| Dec 31, 2023 | -469,000.00 |
| Sep 30, 2023 | -717,000.00 |
| Jun 30, 2023 | -1.60 Mn |
| Mar 31, 2023 | -969,000.00 |
| Dec 31, 2022 | -1.86 Mn |
| Sep 30, 2022 | -1.05 Mn |
| Jun 30, 2022 | -1.01 Mn |
| Mar 31, 2022 | -1.06 Mn |
| Dec 31, 2021 | -509,000.00 |
| Sep 30, 2021 | -51,000.00 |
| Jun 30, 2021 | -1.16 Mn |